Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03401788 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

A Phase 2 study of VHL-Associated Clear Cell Renal Cell Carcinoma and VHL-Associated Renal Cell Carcinoma, sponsored by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Active
Registry status
Phase 2
Development phase
50
Enrollment target
11
Study locations

NCT03401788 is a Phase 2 study of VHL-Associated Clear Cell Renal Cell Carcinoma and VHL-Associated Renal Cell Carcinoma that is active but no longer recruiting, run by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 50 participants. The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03401788, a Phase 2 study of VHL-Associated Clear Cell Renal Cell Carcinoma and VHL-Associated Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
11
Study locations

Study Summary

This study is designed to investigate belzutifan as a treatment for VHL disease associated RCC.

Conditions Studied

VHL-Associated Clear Cell Renal Cell Carcinoma VHL-Associated Renal Cell Carcinoma VHL - Von Hippel-Lindau Syndrome VHL Gene Mutation VHL Syndrome VHL Gene Inactivation

Interventions

  • DRUG Belzutifan

Study Locations (11)

Other

  • Aarhus University Hospital - Aarhus
  • Hospital Georges Pompidou - Paris
  • Cambridge University Hospital - Cambridge

Pennsylvania

  • University of Pennsylvania Medical Center - Philadelphia
  • University of Pittsburgh Medical Center - Pittsburgh

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • University of Michigan - Ann Arbor

Tennessee

  • Vanderbilt Medical Center - Nashville

Texas

  • MD Anderson Cancer Center - Houston

Utah

  • Huntsman Cancer Institute - Salt Lake City

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2018-05-02
Est. Completion 2026-03-29
Phase Phase 2

Sponsor

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03401788

The ClinicalTrials.gov registry entry for NCT03401788 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 6 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with VHL-Associated Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Belzutifan is the first listed.

NCT03401788 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Other, Pennsylvania, Maryland.

Frequently Asked Questions

What is clinical trial NCT03401788 about?

NCT03401788 is a clinical study titled "A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)". This study is designed to investigate belzutifan as a treatment for VHL disease associated RCC.

What is the current status of trial NCT03401788?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2018-05-02. Estimated completion is 2026-03-29.

What conditions does trial NCT03401788 study?

This clinical trial studies the following conditions: VHL-Associated Clear Cell Renal Cell Carcinoma, VHL-Associated Renal Cell Carcinoma, VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome.

What interventions are being tested in trial NCT03401788?

The interventions under investigation include: Belzutifan (DRUG).

Who is sponsoring clinical trial NCT03401788?

This trial is sponsored by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03401788 being conducted?

This trial has 11 study locations across Maryland, Massachusetts, Michigan, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for VHL-Associated Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

VHL-Associated Clear Cell Renal Cell Carcinoma

All registered trials for this condition

VHL-Associated Renal Cell Carcinoma

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.